-

IFF Declares Dividend for First Quarter 2025

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 11, 2025 to shareholders of record as of March 21, 2025.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

© 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

Contacts

Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com

Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com

Industry:

IFF

NYSE:IFF
Release Versions
English
$Cashtags
$IFF

Contacts

Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com

Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com

More News From IFF

IFF and Kemira Form Joint Venture To Produce Sustainable Biobased Materials at Scale

NEW YORK--(BUSINESS WIRE)--IFF (NYSE:IFF) and Kemira announced the formation of Alpha Bio, a joint venture aimed at commercial-scale production of renewable biobased materials. With an investment of approximately €130 million, the Alpha Bio facility will start production in late 2027, converting up to 44,000 MT of plant sugars to bioproducts, including high-performance biopolymers for use in various applications, such as home and personal care and industrial solutions. Alpha Bio’s production wi...

IFF Pharma Solutions Brings Next-Gen Excipient Innovations to CPHI Japan 2025

TOKYO--(BUSINESS WIRE)--IFF (NYSE:IFF) Pharma Solutions will showcase its cutting-edge excipient technologies at CPHI Japan 2025. The IFF Pharma Solutions team will highlight its innovations in oral disintegrating tablets (ODTs), controlled-release formulations, and novel complex formulations at booth 5K-21, Tokyo Big Sight East Halls 4-6, April 9-11. “IFF Pharma Solutions is committed to redefining drug delivery through material science innovation,” said Frank Zhao, commercial leader, IFF Phar...

IFF Announces Expansion of Cedar Rapids, Iowa Ingredients Facility

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) today unveiled plans to expand its Cedar Rapids, Iowa facility to capture a larger share of the booming healthy snacks market both in the U.S. and globally. The 47,000-square-foot expansion represents a nearly $70 million investment. When fully operational in the latter half of 2026, the expansion is projected to create up to 40 new jobs. “Our Cedar Rapids plant will be equipped with cutting-edge technologies, allowing us to provide U.S.-made TAURA by...
Back to Newsroom